Exact Sciences Corp., Madison, already conducting a huge clinical trial on its Cologuard stool-based colorectal cancer test, plans to start a second clinical trial for the use of Cologuard in early 2013. The new project will focus on patients with inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis. Read the full Wisconsin State Journal story here.